Cleo Capital Fund I GP, LLC – Trademark Portfolio
Entity Type: 16
Cleo Capital Fund I GP, LLC has 6 U.S. trademark filings recorded with the United States Patent and Trademark Office (USPTO). Of these, 3 are successfully registered — a 50% registration rate. The portfolio includes marks such as CLEO. Filings span 3 Nice Classification classes, with the highest activity in Class 35 (Advertising & Business) and Class 41 (Education & Entertainment). This trademark owner is based in Santa Monica, CA.
1507 7th St. Suite 519
Santa Monica, CA 90401
Showing of trademarks Trademarks
Trademark Classifications
Cleo Capital Fund I GP, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Education; providing of training; entertainment; sporting and cultural activities
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does Cleo Capital Fund I GP, LLC have?
Cleo Capital Fund I GP, LLC has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 abandoned.
What trademark classes does Cleo Capital Fund I GP, LLC file in?
Cleo Capital Fund I GP, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 41 (Education & Entertainment), Class 36 (Insurance & Financial). Class 35 covers advertising; business management; business administration; office functions.
What are Cleo Capital Fund I GP, LLC's most well-known trademarks?
Cleo Capital Fund I GP, LLC's registered trademark portfolio includes well-known marks such as CLEO. These are among 3 currently registered trademarks in the portfolio.
What is Cleo Capital Fund I GP, LLC's trademark registration success rate?
Cleo Capital Fund I GP, LLC has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.